Who is fezolinetant suitable for?

Fezolinetant is a non-hormonal therapeutic drug that has attracted much attention in recent years. It is mainly used to relieve central vasomotor symptoms caused by estrogen fluctuations in menopausal women, such as hot flashes and night sweats. The mechanism of such symptoms is closely related to the abnormal excitability of hypothalamic neurons. Zonatant restores the balance of the body temperature control system from a neuromodulatory level by selectively blocking neurokinin 3 receptors (NK3R). Therefore, it is especially suitable for menopausal or postmenopausal women. Compared with traditional hormone replacement therapy, the advantage of filzonaitant is that it does not contain estrogen and can avoid risks related to breast, uterus and other tissues that may be caused by hormone use.

From an application perspective, the U.S. Food and Drug Administration (FDA) has approved fezonatant for the treatment of moderate to severe menopausal vasomotor symptoms. Suitable people mainly include women who have lost ovarian function after natural menopause or due to medical reasons. These patients often present with repeated hot flashes, night sweats, mood swings and sleep disorders. Fezonatant offers a new treatment option for patients who cannot tolerate or are not suitable for hormone therapy. The drug may also be considered as an alternative for some women with a history of hormone-sensitive breast cancer or who are contraindicated in taking estrogen drugs because of the risk of blood clots.

Fezonatant has a unique mechanism of action. It directly reduces the frequency of hot flashes caused by abnormal body temperature regulation by inhibiting the over-excitability ofKNDy neurons in the hypothalamus, thereby improving the patient's quality of life. Multiple international studies have shown that it has a rapid onset of action, can significantly relieve symptoms within a few weeks, and is well tolerated. Since the drug does not interfere with sex hormone levels, it has little impact on reproductive organs, bone metabolism and other aspects, and is suitable for long-term management.

However, not all people are suitable for the use of filazonetant. For patients who are still in early perimenopause, have mild symptoms, or are taking other central nervous system drugs, the risks of medication should be assessed under the guidance of a doctor.

Reference materials:https://www.veozah.com/